

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0328/ AM101204(NP)		Application No. 10/659,160		
		Applicant Deborah A. Evrard, et al.				
		Filing Date September 10, 2003		Group 1614		
		Confirmation No. 3728				
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
u	20	0 151 826 A1	08/21/85	EP	X	
	21	0 542 136 A1	05/19/93	EP	X	
	22	2 103 639 A	04/14/72	FR		X
	23	1354554 A	06/05/74	GB	X	
	24	91/13872 A1	09/19/91	WO	X	
	25	94/01437 A1	01/20/94	WO	X	
	26	95/07274 A1	03/16/95	WO	X	
	27	98/16530 A1	04/23/98	WO	X	
a	28	98/40386 A1	09/17/98	WO	X	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
u	29	Birch, A. M. et al., "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D <sub>2</sub> Antagonists/5-HT <sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents," <i>J Med Chem</i> , 1999, 42, 3342-3355				
EXAMINER <i>Chy</i>				DATE CONSIDERED 4/14/05		



Sheet 1 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0328/ AM101204(NP)	Application No. 10/659,160
		Applicant Deborah A. Evrard, et al.	
		Filing Date September 10, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	1	Artigas, F., et al., "Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors," <i>Arch Gen Psychiatry</i> , March 1994, 51, 248-251	
	2	Blier, P., et al., "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression," <i>J. of Clinical Psychopharmacology</i> , 1995, 15(3), 217-222	
	*	3	Bundgaard, (Ed.), Design of Prodrugs, <i>Elsevier</i> , 1985
		4	Bundgaard, H., "Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs," <i>Advanced Drug Deliver Reviews</i> , 1992, 8, 1-38
	*	5	Bundgaard, <i>J. of Pharmaceutical Sciences</i> , 1988, 7(285 et seq.)
		6	Cheetham, S.C., et al., "[ <sup>3</sup> H]paroxetine binding in rat frontal cortex strongly correlates with [ <sup>3</sup> H]5-HT uptake: effect of administration of various antidepressant treatments," <i>Neuropharmacol.</i> , 1993, 32(8), 737-743
	*	7	Eliel, E.L., Stereochemistry of Carbon Compounds, <i>McGraw-Hill</i> , NY, 1962
	*	8	Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems, <i>American Chemical Society</i> , 1975
	*	9	Jacques, et al., Enantiomers, Racemates and Resolutions, <i>Wiley Interscience</i> , NY, 1981
		10	Krogsgaard-Larsen, et al. (Eds.), "Design and Application of Prodrugs," <i>Textbook of Drug Design and Development</i> , 1991, Chap. 5, 113-191
EXAMINER		DATE CONSIDERED 4/14/03	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Sheet 2 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0328/ AM101204(NP)	Application No. 10/659,160
		Applicant Deborah A. Evrard, et al.	
		Filing Date September 10, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
a	11	Lazareno, S., et al., "Pharmacological characterization of acetylcholine-stimulated [ <sup>3</sup> S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies," <i>Br. J. Pharmacol.</i> , 1993, 109, 1120-1127	
	12	Ostrowski, S., "A synthesis of fused pyrimidine mono-n-oxides," <i>Heterocycles</i> , 1996, 43(2), page 389-396	
	13	Perez, V., et al., "Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment," <i>The Lancet</i> , May 31, 1997, 349, 1594-1597	
*	14	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., Gennaro, A.R. (Ed.), <i>Mack Publishing Company, Easton, PA, 1985</i>	
	15	Tome, M.B., et al., "Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol," <i>J. Affect Disord</i> , 1997, 44, 101-109	
	16	Tome, M.B., et al., "Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency," <i>Int. Clin. Psychopharmacol</i> , 1997, 12, 81-89	
*	17	Widder, et al. (Eds.), <i>Methods in Enzymology, Academic Press, 1985, Vol. 4</i>	
	18	Wilen, S.H., "Tables of Resolving Agents and Optical Resolutions," <i>Univ. of Notre Dame Press, Notre Dame, IN, E.L. Eliel (Ed.), 1972, page 268-298</i>	
u	19	Wilen, S.H., et al., "Strategies in optical resolutions," <i>Tetrahedron</i> , 1977, 33, 2725-2736	
EXAMINER		DATE CONSIDERED 4/14/05	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.